Quest Diagnostics Inc (DGX)

DGX (NYSE:Health Services)
pos +0.09
Today's Range: 59.95 - 62.07 | DGX Avg Daily Volume: 1,168,800
Last Update: 10/22/14 - 4:01 PM EDT
Volume: 2,013,955
YTD Performance: 14.16%
Open: $60.93
Previous Close: $61.12
52 Week Range: $50.46 - $64.38
Oustanding Shares: 144,414,683
Market Cap: 8,614,335,841
6-Month Chart
TheStreet Ratings Grade for DGX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 13 13 13 13
Moderate Sell 0 0 0 0
Strong Sell 3 3 3 3
Mean Rec. 3.07 3.07 3.07 3.07
Latest Dividend: 0.33
Latest Dividend Yield: 2.11%
Dividend Ex-Date: 10/03/14
Price Earnings Ratio: 11.94
Price Earnings Comparisons:
DGX Sector Avg. S&P 500
11.94 11.30 27.46
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.61% 5.05% 22.51%
Revenue -3.20 -0.03 -0.01
Net Income 49.10 0.12 0.04
EPS 60.60 0.37 0.11
Earnings for DGX:
Revenue 7.15B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.08 $1.04 $4.04 $4.34
Number of Analysts 14 13 15 15
High Estimate $1.13 $1.08 $4.07 $4.47
Low Estimate $1.04 $0.99 $3.98 $4.19
Prior Year $1.02 $1.03 $4.00 $4.04
Growth Rate (Year over Year) 5.39% 1.42% 0.95% 7.48%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Get Some Positive Lab Results Real Money Pro($)

Try this options play for the sometimes volatile Bio-Reference Laboratories.
May 08, 2014 | 7:58 AM EDT
DGX was upgraded to Neutral from Underperform, Bank of America/Merrill Lynch said. $58 price target. Had positive meetings with managem...
Apr 14, 2014 | 8:19 AM EDT
Shares of DGX now seen reaching $62, according to Credit Suisse. Estimates also upped, given better reimbursement trends and the Solsta...
Feb 25, 2014 | 7:12 AM EST
RBC Capital Markets Healthcare Conference
Jan 31, 2014 | 8:10 AM EST
DGX cut its numbers, UBS said. 1Q14 expected to be impacted by sequestration and weather. $56 price target and Neutral rating. 
Quest Diagnostics -- and others in this beaten-down sector -- are excellent trading vehicles.
Dec 10, 2013 | 7:23 AM EST
DGX was downgraded to Underperform, Bank of America/Merrill Lynch said. $55 price target. Expect weak growth and pricing prospects to c...
Aug 08, 2013 | 7:59 AM EDT
DGX was upgraded from Hold to Buy, Maxim Group said. $73 price target. New management team is cutting costs and working to restore grow...
Jul 19, 2013 | 8:09 AM EDT
DGX estimates were raised on increased buybacks, said UBS. Price target increased to $61.
Jul 12, 2013 | 7:16 AM EDT
DGX was initiated with a Neutral rating, Robert Baird said. $58 price target. Turnaround story may still take some time.   

Columnist Conversations

CHECK IT OUT HERE Lot's of great out and underperformer picks, as well as M&A ideas that you don't always ...
The major market indices continue to move within the parameters of the Fibonacci retracement levels measured o...
Since we cleared a key decision on the way up, I want to watch this pullback for an entry if it fires off a bu...
Conclusion DDD is down today on new that the firm has cut revenue forecast due to production issues. The issue...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.